PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Gane, Edward J.
TI  - SOF Plus GS-5816 Effective in Noncirrhotic Patients Infected with HCV GT-3: ELECTRON-2 Final Results
DP  - 2014  01
TA  - MD Conference Express
PG  - 13--14
VI  - 14
IP  - 48
4099  - http://mdc.sagepub.com/content/14/48/13.short
4100  - http://mdc.sagepub.com/content/14/48/13.full
AB  - Sofosbuvir (SOF)has potent activity against hepatitis C virus (HCV). Unpublished studies have also indicated the anti-HCV activity of GS-5816, and the high SVR following a 12-week regimen in noncirrhotic, treatment-naïve HCV patients. These studies spurred the phase 2, open-label, ELECTRON-2 study evaluating the efficacy and safety of an 8-week regimen of SOF + GS-5816 in noncirrhotic, treatment-naïve patients infected with HCV genotype 3, as discussed in this article.